3 results
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMOCompleted
Primary Objective: To assess which method for measuring muscle mass is most reliable compared to dual-energy X-ray absorptiometry (DEXA) scan in a population with class II/III obesity.Secondary Objectives:1. To assess which combination of methods…
Approved WMORecruiting
• to assess the efficacy of the sequential combination strategy of front-line afatinib-chemo, followed by a treatment with osimertinib-chemo in those patients that develop a T790M mutation as a mechanism of resistance.